• PDF / 170,628 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 97 Downloads / 217 Views

DOWNLOAD

REPORT

20/0860-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 22 Aug 2020 No. 860

1

Recommend Documents

Atorvastatin cost effective in T2DM

163 57 182KB

Intensive lifestyle intervention cost effective for obesity and T2DM?

153 96 182KB

Intervention programme controlling dementia risk factors cost effective

138 33 163KB

Dapagliflozin cost-saving alternative to DPP-4 inhibitors in T2DM

179 74 166KB

Canagliflozin in T2DM-related nephropathy improves QALYs, reduces cost

181 44 164KB

New basal insulins in T2DM: cost not increased, hypoglycaemia reduced

144 34 169KB

New basal insulins in T2DM: cost not increased, hypoglycaemia reduced

146 63 184KB

Cost-Effective

168 109 57MB

Atomoxetine cost-effective in ADHD

158 88 139KB

Highly Cost-Effective Intervention

195 83 57MB

Synflorix cost effective versus PCV13 in Taiwan

208 39 182KB

Trastuzumab cost effective in early breast cancer

115 43 122KB